FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2538445437> ?p ?o ?g. }

• W2538445437 abstract "Abstract Bortezomib (Velcade®) is effective in MM as single agent. A strong rationale supports the association of bortezomib with anthracyclines. Bortezomib may increase the activity of anthracyclines by inhibiting maturation of P-gp, suppressing DNA repair and inducing phosphorylation and cleavage of Bcl-2. Anthracyclines down-regulate the bortezomib anti-apoptotic effect. In vitro studies demonstrated that liposome encapsulated doxorubicin can overcome MDR-1 overexpression. It has a longer half-life, lower cardiac toxicity and comparable efficacy. Thus, we added non-pegylate liposomal doxorubicin (Myocet®) to the low dose VTD regimen (Ciolli et al. Leukemia & Lymphoma2006;47(1): 171–173). Aims of the study were to evaluate the feasibility of treatment and stem cells harvest and transplantation, to compare ORR and TTP in respect to LD-VTD. The study was performed in accordance with the Declaration of Helsinki. Eligibility criteria: pts primary refractory (PR) or relapsed and refractory (R/R), with a LVEF more than 45% and a measurable disease. Therapy: bortezomib 1.0 mg/m2 i.v. bolus days 1, 4, 8 and 11 of a 28-d cycle, Myocet 50 mg/m2 i.v over 60 minutes on day 4 (1 hour after bortezomib), oral dexamethasone 24 mg on the day of and the day following each bortezomib dose. Thalidomide 100 mg/d if non controindicated. All toxicities were defined according to NCI criteria. Response was evaluated after each cycle. Pts with progressive disease (PD) were removed from the study, the others continued until best response for a maximum of 4 cycles. Time to response was from the date of the first administration of bortezomib to the first evidence of response. From June 2005, 28 pts, median age 68 years, entered the study: 5 stage IIA, 20 IIIA and 3 IIIB. 16 (57%) were the PR pts and 12(43%) those R/R. 8(29%) had a β2microglobulin &gt;4 mg/L, 7 a PS &gt;2 and 8 a pre-existing peripheral neuropathy (PN) grade 2. Median time from diagnosis was 4 years and a median of 4 (range 2–6) were the prior therapy lines. All pts had previously received thalidomide plus dexamethasone; 8 had previously received bortezomib. 13 (46%) did not receive thalidomide due to a pre-existing neurological toxicity. Haematological toxicity was registered 14–17 days from the start of therapy and lasted for a maximum of 4 days: grade 2 neutropenia in 3 pts, grade 4 thrombocytopenia in 5. A patient had a grade 4 gastric haemorrhage. 3 pts had pneumonia, 2 HZ infection and 1 a DVT. Other adverse advents of grade &gt;1 were fatigue (50%), nausea (60%), diarrhoea (15%), alopecia (10%). None progression of PN was observed. No patient experienced clinical evidence of cardiac toxicity. At July 31th 2006,. all pts were valuable for response: 3 PD, 4 SD, 21 responders: 8 CR, 2 nCR, 7 PR,4 MR (ORR 75%). Median time to best response was 1 month (range 1– 2). 3 pts successfully harvested the PBSC and 1 was transplanted. After a median follow-up of 9 months, median TTP and OS had not been reached, 23 pts were alive and 5 (2 PD and 3 responders) had died. Myocet did not add toxicity to LD-VTD. PBSC has been successfully performed in eligible pts. More pts and an adequate follow-up are needed to draw any definitive conclusion about TTP and OS, however, this regimen appears feasible and effective with an increased ORR compared to our previous LD-VTD experience (75% vs 53%)." @default.
• W2538445437 created "2016-10-28" @default.
• W2538445437 creator A5000684645 @default.
• W2538445437 creator A5008647277 @default.
• W2538445437 creator A5039833411 @default.
• W2538445437 creator A5065081503 @default.
• W2538445437 creator A5066243779 @default.
• W2538445437 date "2006-11-16" @default.
• W2538445437 modified "2023-09-27" @default.
• W2538445437 title "Liposomal Doxorubicin (Myocet®) Enhance the Efficacy of Bortezomib, Dexamethasone Plus Thalidomide in Refractory Myeloma." @default.
• W2538445437 doi "https://doi.org/10.1182/blood.v108.11.5087.5087" @default.
• W2538445437 hasPublicationYear "2006" @default.
• W2538445437 type Work @default.
• W2538445437 sameAs 2538445437 @default.
• W2538445437 citedByCount "4" @default.
• W2538445437 countsByYear W25384454372020 @default.
• W2538445437 crossrefType "journal-article" @default.
• W2538445437 hasAuthorship W2538445437A5000684645 @default.
• W2538445437 hasAuthorship W2538445437A5008647277 @default.
• W2538445437 hasAuthorship W2538445437A5039833411 @default.
• W2538445437 hasAuthorship W2538445437A5065081503 @default.
• W2538445437 hasAuthorship W2538445437A5066243779 @default.
• W2538445437 hasConcept C126322002 @default.
• W2538445437 hasConcept C143998085 @default.
• W2538445437 hasConcept C2776364478 @default.
• W2538445437 hasConcept C2776694085 @default.
• W2538445437 hasConcept C2777478702 @default.
• W2538445437 hasConcept C2779609412 @default.
• W2538445437 hasConcept C2780401358 @default.
• W2538445437 hasConcept C2781303535 @default.
• W2538445437 hasConcept C2781413609 @default.
• W2538445437 hasConcept C2911091166 @default.
• W2538445437 hasConcept C71924100 @default.
• W2538445437 hasConcept C98274493 @default.
• W2538445437 hasConceptScore W2538445437C126322002 @default.
• W2538445437 hasConceptScore W2538445437C143998085 @default.
• W2538445437 hasConceptScore W2538445437C2776364478 @default.
• W2538445437 hasConceptScore W2538445437C2776694085 @default.
• W2538445437 hasConceptScore W2538445437C2777478702 @default.
• W2538445437 hasConceptScore W2538445437C2779609412 @default.
• W2538445437 hasConceptScore W2538445437C2780401358 @default.
• W2538445437 hasConceptScore W2538445437C2781303535 @default.
• W2538445437 hasConceptScore W2538445437C2781413609 @default.
• W2538445437 hasConceptScore W2538445437C2911091166 @default.
• W2538445437 hasConceptScore W2538445437C71924100 @default.
• W2538445437 hasConceptScore W2538445437C98274493 @default.
• W2538445437 hasLocation W25384454371 @default.
• W2538445437 hasOpenAccess W2538445437 @default.
• W2538445437 hasPrimaryLocation W25384454371 @default.
• W2538445437 hasRelatedWork W1963690178 @default.
• W2538445437 hasRelatedWork W1967461244 @default.
• W2538445437 hasRelatedWork W2003559211 @default.
• W2538445437 hasRelatedWork W2112489854 @default.
• W2538445437 hasRelatedWork W2115189075 @default.
• W2538445437 hasRelatedWork W2427804748 @default.
• W2538445437 hasRelatedWork W2530787370 @default.
• W2538445437 hasRelatedWork W2597085350 @default.
• W2538445437 hasRelatedWork W2957896353 @default.
• W2538445437 hasRelatedWork W2968865251 @default.
• W2538445437 isParatext "false" @default.
• W2538445437 isRetracted "false" @default.
• W2538445437 magId "2538445437" @default.
• W2538445437 workType "article" @default.